Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.

Yin Y, Ren X, Smith C, Guo Q, Malabunga M, Guernah I, Zhang Y, Shen J, Sun H, Chehab N, Loizos N, Ludwig DL, Ornitz DM.

Dis Model Mech. 2016 May 1;9(5):563-71. doi: 10.1242/dmm.024760. Epub 2016 Apr 7.

2.

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.

Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, Pandolfi PP, Nimer SD.

Clin Cancer Res. 2008 Feb 1;14(3):826-32. doi: 10.1158/1078-0432.CCR-07-0318.

3.

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.

Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP.

Nature. 2006 Aug 17;442(7104):779-85.

PMID:
16915281
4.

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S.

Leukemia. 2006 Feb;20(2):212-7.

PMID:
16357841
5.

The PML-nuclear body associated protein Daxx regulates the cellular response to CD40.

Salomoni P, Guernah I, Pandolfi PP.

Cell Death Differ. 2006 Apr;13(4):672-5. No abstract available.

6.

Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.

Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP.

Nature. 2005 Jan 20;433(7023):278-85.

Supplemental Content

Loading ...
Support Center